Dr. Paul Obeng is a Senior Specialist Clinical Pharmacist in Pediatric Haematology Oncology at the Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. He holds a Bachelor of Pharmacy, a Master of Public Health and Doctor of Pharmacy from the Kwame Nkrumah University of Science and Technology (KNUST).
He is a Fellow in Clinical Pharmacy (Haematology Oncology) at the West Africa Postgraduate College of Pharmacists (WAPCP). He is currently the Head of Clinical Pharmacy in Paediatric Haematology Oncology at KATH and doubles as an adjunct lecturer at KNUST, WAPCP and Ghana College of Nurses and Midwifes.
He is a 2018 Global Health Fellow at the Novartis Institutes of Biomedical Research (NIBR), Cambridge USA where he had extensive training in clinical trials. He is the study Pharmacist at the Kumasi Centre for Sickle Cell Disease (KCSCD) and has been involved in clinical trials including the Severe Malaria in African Children (SMAC), AQUAMAT, Barekuma Multinutrient and HESTIA 3 trials.
Currently, he is the Study Pharmacist for STAND and GBT131/132 and a Fellow of the Sickle Pan-African Research Consortium (SPARCO). With his extensive research and knowledge in Hydroxyurea (HU), he has been the focal Pharmacist involved in the design and implementation of HU protocol for the management of patients with SCD in the sickle cell unit of KATH.
He was a Consultant Pharmacist for the Hydroxyurea Working Group established by Novartis/Sandoz and currently an active member of the International Society of Oncology Pharmacy Practitioners (ISOPP) and International Society of Paediatric Oncology (SIOP), Oncology Pharmacists Association of Ghana (OPAG) and Pharmaceutical Society of Ghana (PSGH).
The Role of The Pharmacist In The Management of Sickle Cell Disease
Paediatric Chemotherapy in Sub-Saharan Africa